AVTR · Avantor, Inc.

The thesis

Avantor's recovery case still rests on one test: whether Q3 results, due before the market opens on 28 October 2026, deliver the organic revenue growth of about 250 basis points (2.5%) and adjusted earnings per share (EPS) of $0.20–$0.21 that management guided on 29 July 2026. The shares closed at $15.34 on 2 October 2026, above the $14 targets set by Morgan Stanley, RBC and Evercore ISI on 30 July 2026, so the report has to confirm the guidance rather than merely meet a lower bar.

Two things changed since the 20 September 2026 note. Avantor named Todd Garner Executive Vice President and Chief Financial Officer effective 21 September 2026, ending the interim arrangement led by Steve Eck. The Q3 report date is now confirmed by the company, replacing the earlier estimate.

The narrative is maturing: the recovery guidance of 29 July 2026 is well known, the 3-month share gain is 50.4% through 2 October 2026, and the newest company news is a leadership appointment, not an operating beat.

Bullish and bearish views on Avantor, Inc.

The bull case on Avantor, Inc. (AVTR), in brief: Guidance was raised on a beat. The bear case: The shares sit above most targets.

Bull case

• Guidance was raised on a beat. On 29 July 2026 Avantor reported Q2 adjusted EPS of $0.21 against a $0.19 estimate and sales of $1.692 billion against $1.612 billion, and lifted FY2026 adjusted EPS guidance to $0.80–$0.83 from $0.77–$0.83 (Benzinga, 29 July 2026). The same day it moved FY2026 organic growth guidance to -0.5% to +0.5% from -2.5% to -0.5%.
• Distribution returned to organic growth. VWR Distribution & Services posted Q2 organic growth of 1.7% on sales of $1,240.5 million (Q2 2026 earnings release, 29 July 2026). The segment is roughly 73% of revenue, so its direction drives the company result.
• Adjusted net leverage was 3.3 times at 30 June 2026.
• Finance leadership is settled. Garner was CFO of CONMED from 2018 to March 2026 and took the role at Avantor on 21 September 2026 (company 8-K). A permanent CFO ahead of the 8 December 2026 Investor Day removes an open question about who presents the medium-term targets.
• Analyst targets are moving up. UBS assumed coverage at Neutral with a $16 target on 9 September 2026, and Wells Fargo set Overweight with a $16 target on 30 July 2026. Bank of America was reported to have moved to $16.50 from $14, a change not dated in the sources reviewed.

Bear case

• The shares sit above most targets. The close of $15.34 on 2 October 2026 compares with a third-party aggregator average 12-month target of $14.56 across 16 analysts, with a consensus rating of Hold. Stifel's target is $15 (30 July 2026), and Morgan Stanley, RBC and Evercore each sit at $14.
• Revenue is still not growing. Q2 company organic revenue fell 0.4% (Q2 2026 earnings release, 29 July 2026), and the full-year range still includes a small decline. A 50.4% three-month gain has priced in a recovery that the reported numbers have not yet shown for a full year.
• UBS wants operating proof. In its 9 September 2026 note UBS cited weak biopharma production, margin pressure and the need to turn stronger orders into sustained growth, and kept Neutral.
• Earnings quality is thin. Q2 diluted GAAP EPS was $0.06 against $0.21 adjusted, and all guidance is quoted on the adjusted figure (Q2 2026 earnings release, 29 July 2026).
• Debt remains heavy. Gross debt was $3,715.4 million against $306.8 million of cash at 30 June 2026, so a small change in growth moves equity value by more than it would for a lightly indebted peer.

Price setup

Adjusted daily closes show $15.34 on 2 October 2026, 3.3% below the 52-week high of $15.86. The 14-day relative strength index (RSI, a 0-100 momentum gauge) was 52.8, a neutral reading that shows the shares have paused after the climb rather than extended it.

The $14.00 area is the first support level that matters, because it matches the cluster of July analyst targets from Morgan Stanley, RBC and Evercore. A weekly close below it would put the shares back inside the range that analysts set before Q3 evidence arrived.

Crowding evidence: the 3-month gain of 50.4% has outrun the consensus target, and the Q3 report is 26 days away from the 2 October 2026 close. Law-firm Bronstein, Gewirtz & Grossman announced an investigation of potential claims for Avantor securities purchasers on 4 August 2026. No insider or share-issuance filings were found in the period reviewed.

Catalysts, next 30 days

• 28 October 2026, before the open: Q3 2026 results, with a conference call at 8:00 a.m. Eastern (company announcement). The test is organic growth near 2.5%, adjusted EPS of $0.20–$0.21, retention of the -0.5% to +0.5% FY2026 organic range, and Q3 adjusted net leverage at or below 3.3 times.
• 8 December 2026, outside the window: Investor Day in New York City, announced on the 29 July 2026 call. It is the first venue for the new CFO to present medium-term targets.

What would change the view

The case breaks if Q3 organic growth lands clearly below the roughly 2.5% guided, if management lowers the FY2026 organic range of -0.5% to +0.5%, or if VWR Distribution & Services reports negative organic growth after +1.7% in Q2. A cut to the FY2026 free cash flow guidance of $500–$550 million, or adjusted net leverage above 3.3 times, would break the deleveraging half of the case.

On price, a weekly close below $14.00 would show the market no longer paying for the recovery. A clean Q3 beat with the guidance range raised again would strengthen the case, since the shares would then be valued on results above the July targets.

What it trades with

Avantor supplies labs and bioprocess customers, so its results follow biopharma production volumes and research funding more than the broad market. Life-science tools and distribution peers report in the same weeks, and their comments on customer ordering can move Avantor ahead of its own 28 October 2026 report. The 17 September 2026 expansion of RIM single-use bioprocessing products across Asia Pacific ties the company to bioprocessing demand; the announcement did not quantify revenue.